These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 26856832)

  • 21. Exploring resistance pathways for first-generation NS3/4A protease inhibitors boceprevir and telaprevir using Bayesian network learning.
    Cuypers L; Libin P; Schrooten Y; Theys K; Di Maio VC; Cento V; Lunar MM; Nevens F; Poljak M; Ceccherini-Silberstein F; Nowé A; Van Laethem K; Vandamme AM
    Infect Genet Evol; 2017 Sep; 53():15-23. PubMed ID: 28499845
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Natural Polymorphisms Conferring Resistance to HCV Protease and Polymerase Inhibitors in Treatment-Naïve HIV/HCV Co-Infected Patients in China.
    Zhou K; Liang Z; Wang C; Hu F; Ning C; Lan Y; Tang X; Tucker JD; Cai W
    PLoS One; 2016; 11(6):e0157438. PubMed ID: 27341031
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Polymorphisms and resistance mutations of hepatitis C virus on sequences in the European hepatitis C virus database.
    Kliemann DA; Tovo CV; da Veiga AB; de Mattos AA; Wood C
    World J Gastroenterol; 2016 Oct; 22(40):8910-8917. PubMed ID: 27833382
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Worldwide prevalence of baseline resistance-associated polymorphisms and resistance mutations in HCV against current direct-acting antivirals.
    Palanisamy N; Kalaghatgi P; Akaberi D; Lundkvist Å; Chen ZW; Hu P; Lennerstrand J
    Antivir Ther; 2018; 23(6):485-493. PubMed ID: 29745936
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HCV NS5A resistance-associated variants in a group of real-world Japanese patients chronically infected with HCV genotype 1b.
    Hirotsu Y; Kanda T; Matsumura H; Moriyama M; Yokosuka O; Omata M
    Hepatol Int; 2015 Jul; 9(3):424-30. PubMed ID: 25791176
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevalence of naturally occurring NS5A resistance-associated substitutions in patients infected with hepatitis C virus subtype 1a, 1b, and 3a, co-infected or not with HIV in Brazil.
    Malta F; Gaspareto KV; Lisboa-Neto G; Carrilho FJ; Mendes-Correa MC; Pinho JRR
    BMC Infect Dis; 2017 Nov; 17(1):716. PubMed ID: 29132303
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevalence of resistant associated variants (RAVs) in the naïve HCV patient candidate for direct acting antiviral (DAA) therapy.
    Karbalaie Niya MH; Salman-Tabar S; Bokharaei-Salim F; Behmanesh M; Keyvani H
    Microb Pathog; 2017 Apr; 105():166-170. PubMed ID: 28161357
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting a host-cell entry factor barricades antiviral-resistant HCV variants from on-therapy breakthrough in human-liver mice.
    Vercauteren K; Brown RJ; Mesalam AA; Doerrbecker J; Bhuju S; Geffers R; Van Den Eede N; McClure CP; Troise F; Verhoye L; Baumert T; Farhoudi A; Cortese R; Ball JK; Leroux-Roels G; Pietschmann T; Nicosia A; Meuleman P
    Gut; 2016 Dec; 65(12):2029-2034. PubMed ID: 26306759
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Implications of baseline polymorphisms for potential resistance to NS3 protease inhibitors in Hepatitis C virus genotypes 1a, 2b and 3a.
    Palanisamy N; Danielsson A; Kokkula C; Yin H; Bondeson K; Wesslén L; Duberg AS; Lennerstrand J
    Antiviral Res; 2013 Jul; 99(1):12-7. PubMed ID: 23648709
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of hepatitis C NS5A resistance associated polymorphisms using ultra deep single molecule real time (SMRT) sequencing.
    Bergfors A; Leenheer D; Bergqvist A; Ameur A; Lennerstrand J
    Antiviral Res; 2016 Feb; 126():81-9. PubMed ID: 26707078
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Frequency distribution of HCV resistance-associated variants in infected patients treated with direct-acting antivirals.
    Cabral BCA; Ramos JA; Silveira ALM; Nascimento ÉRDS; Ferreira SB; Coelho HSM; Moura-Neto RS; Villela-Nogueira CA; Hoffmann L; Silva R
    Int J Infect Dis; 2022 Feb; 115():171-177. PubMed ID: 34902582
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevalence of NS5B resistance-associated variants in treatment-naïve Asian patients with chronic hepatitis C.
    Yang S; Xing H; Feng S; Ju W; Liu S; Wang X; Ou W; Cheng J; Pan CQ
    Arch Virol; 2018 Feb; 163(2):467-473. PubMed ID: 29143142
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Determination of drug resistance mutations of NS3 inhibitors in chronic hepatitis C patients infected with genotype 1].
    Şanlıdağ T; Sayan M; Akçalı S; Kasap E; Buran T; Arıkan A
    Mikrobiyol Bul; 2017 Apr; 51(2):145-155. PubMed ID: 28566078
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Distribution of natural resistance to NS3 protease inhibitors in hepatitis C genotype 1a separated into clades 1 and 2 and in genotype 1b of HIV-infected patients.
    Bagaglio S; Uberti-Foppa C; Messina E; Merli M; Hasson H; Andolina A; Galli A; Lazzarin A; Morsica G
    Clin Microbiol Infect; 2016 Apr; 22(4):386.e1-386.e3. PubMed ID: 26706617
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Naturally occurring NS3 resistance-associated variants in hepatitis C virus genotype 1: Their relevance for developing countries.
    Echeverría N; Betancour G; Gámbaro F; Hernández N; López P; Chiodi D; Sánchez A; Boschi S; Fajardo A; Sóñora M; Moratorio G; Cristina J; Moreno P
    Virus Res; 2016 Sep; 223():140-6. PubMed ID: 27449600
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The incidence of resistance-associated variants to NS5A in HCV subtypes 1a and 1b in Taiwan.
    Tsai MC; Hung CH; Lu SN; Wang JH; Chen CH; Kee KM; Chang KC; Chao TL; Hu TH
    Biomed J; 2021 Dec; 44(6 Suppl 1):S126-S131. PubMed ID: 35123932
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of Naturally Occurring Resistance-Associated Substitutions Between 2008 and 2016 in Chinese Patients with Chronic Hepatitis C Virus Infection.
    Huang W; Wang M; Gong Q; Yu D; Chen P; Lin J; Han Y; Su Y; Qu L; Zhang X
    Microb Drug Resist; 2019; 25(6):944-950. PubMed ID: 30702389
    [No Abstract]   [Full Text] [Related]  

  • 38. Impact of Preexisting Hepatitis C Virus Genotype 6 NS3, NS5A, and NS5B Polymorphisms on the
    McPhee F; Ueland J; Vellucci V; Bowden S; Sievert W; Zhou N
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30718256
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antiviral therapy of hepatitis C in 2014: do we need resistance testing?
    Schneider MD; Sarrazin C
    Antiviral Res; 2014 May; 105():64-71. PubMed ID: 24583028
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pretreatment Hepatitis C Virus NS5A/NS5B Resistance-Associated Substitutions in Genotype 1 Uruguayan Infected Patients.
    Aldunate F; Echeverría N; Chiodi D; López P; Sánchez-Cicerón A; Fajardo A; Soñora M; Cristina J; Hernández N; Moreno P
    Dis Markers; 2018; 2018():2514901. PubMed ID: 30186532
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.